Synapse - Works

Results (2899)

Outcomes of subsequent anti-lymphoma therapies in patients (pts) with large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel) or standard of care (SOC) in the second-line (2L) ZUMA-7 study

Meeting Abstract

Ghobadi, A.; Munoz, J.; Westin, J.; Locke, F. L.; Miklos, D. B.; Rapoport, A. P.; Perales, M. A.; Reagan, P. M.; McGuirk, J. P.; Jacobson, C. A.; more...
Blood (2022)

Fulltext@MSK | Save

Initial treatment response is prognostic and predictive of relapse patterns: Outcomes of >500 patients treated for primary CNS lymphoma

Meeting Abstract

Tringale, K. R.; Yahalom, J.; Scordo, M.; Cederquist, G. Y.; Vachha, B.; Schaff, L.; Hajj, C.; Hubbeling, H.; Zhang, Z.; White, C.; more...
Blood (2022)

Fulltext@MSK | Save

A phase 2 study of pembrolizumab (MK-3475) after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma

Meeting Abstract

Merrill, M. H.; Dahi, P. B.; Redd, R. A.; McDonough, M. M.; Chen, Y. B.; LaCasce, A. S.; Fisher, D. C.; Herrera, A. F.; Jacobson, C. A.; Kim, A. I.; more...
Blood (2022)

Fulltext@MSK | Save

Attenuation of graft-versus-host-disease via genetic or pharmacologic inhibition of the RNA splicing factor RBM39

Meeting Abstract

Bourcier, J.; Hogg, S. J.; Erickson, C.; Singer, M. E.; Tittley, S.; Ito, T.; Egorova, A.; Kuttiyara, J.; Hanash, A. M.; Abdel-Wahab, O.; more...
Blood (2022)

Fulltext@MSK | Save

Microbial bile acid metabolism shapes effector T cell responses during inflammation in mouse and human

Meeting Abstract

Lindner, S.; Miltiadous, O.; Ramos, R. J.; Dai, A.; Kousa, A.; Armijo, G. K.; Ghale, R.; Nguyen, C. L.; Paredes Sanchez, J.; Fei, T.; more...
Blood (2022)

Fulltext@MSK | Save

Donor-derived amphiregulin drives CD4(+) T cell expansion and promotes tissue pathology after experimental allogeneic BMT

Meeting Abstract

Ito, T.; Takashima, S.; Calafiore, M.; Fu, Y. Y.; Egorova, A.; Kuttiyara, J.; Chang, W.; Vinci, P.; Arnhold, V.; Zaiss, D.; more...
Blood (2022)

Fulltext@MSK | Save

Genomic determinants of resistance in newly diagnosed multiple myeloma treated with targeted-immunotherapy

Meeting Abstract

Maura, F.; Boyle, E.; Coffey, D.; Maclachlan, K. H.; Diamond, B.; Blaney, P.; Gagler, D.; Ziccheddu, B.; Ghamlouch, H.; Wang, Y.; more...
Blood (2022)

Fulltext@MSK | Save

Predictors and outcomes of immune effector cell associated neurotoxicity syndrome in patients receiving chimeric antigen receptor T-cell therapy for aggressive B-cell non-Hodgkin lymphoma

Meeting Abstract

Patel, V.; Bhaskar, S.; Schuster, S. J.; Nastoupil, L. J.; Perales, M. A.; Shouval, R.; McGuirk, J. P.; Maziarz, R. T.; Chen, A.; Bachanova, V.; more...
Blood (2022)

Fulltext@MSK | Save

Analysis of 372 adult allograft recipients reveals associations between non-European ancestry, low socioeconomic status, and receipt of HLA-disparate grafts

Meeting Abstract

Fingrut, W.; Chinapen, S.; Katrichis, A.; Carino, C.; Davis, E.; Shaffer, B. C.; Cho, C.; Shah, G. L.; Barker, J. N.
Blood (2022)

Fulltext@MSK | Save

Fc-mediated antibody effector function, inflammation resolution and oligoclonality on TCR rearrangements predict sustained MRD negativity in newly diagnosed multiple myeloma treated with immunotherapy regimens

Meeting Abstract

Boyle, E. M.; Maura, F.; Coffey, D.; Maclachlan, K. H.; Diamond, B.; Ghamlouch, H.; Gagler, D.; Blaney, P.; Ziccheddu, B.; Wang, Y.; more...
Blood (2022)

Fulltext@MSK | Save